FlowDesk — News

Headlines

Bullish tone

Bearish tone

Symbol-tagged

News sentiment over time

Daily average lexicon sentiment across 202 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.

Yahoo2026-09-09T12:00:00+00:00

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apneaU.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026 NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biop

IXHL

Yahoo2026-08-25T12:46:00+00:00

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designationNEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the first patient has been

IXHL

Diagnostics

sourcesearch:live+archive

count2

archive_hits0

hintWorker/cron → market_news table for the default view; search spans the permanent news_archive plus a live Finnhub top-up